Table 1

Baseline patient characteristics by MBDA category

MBDA score and category
N (patients)
Overall
n=17 433
<30 (low)
n=2393
30–44 (moderate)
n=6887
>44 (high)
n=8153
Age in years, mean (SD)68.9 (10.7)66.3 (11.4)69.2 (10.3)69.5 (10.6)
MBDA score*, mean (SD)44.1 (14.0)21.9 (5.3)37.9 (4.1)55.8 (9.2)
Female, %79.072.080.180.0
Race, %
 Black9.77.78.911.0
 White80.779.481.480.4
 Other9.613.09.78.6
Comorbidities, %
 Acute myocardial infarction†1.10.51.01.3
 Coronary heart disease20.316.119.622.0
 Heart failure7.13.05.39.8
 Stroke6.04.75.66.6
 Abdominal aortic aneurysm1.10.81.11.1
 Peripheral arterial disease3.42.33.23.9
 Atrial fibrillation7.94.66.89.8
 Diabetes25.017.822.629.2
 Hyperlipidaemia55.451.557.055.2
 Hypertension67.256.065.272.1
 Obesity7.24.46.68.6
 Smoking12.29.511.014.1
 Chronic kidney disease11.66.19.714.8
 Chronic obstructive pulmonary disease25.419.323.029.2
 Pneumonia5.32.64.17.0
 Sepsis1.80.51.42.5
Medication use, %
 Biologic DMARDs37.040.838.035.0
 HCQ, LEF or SSZ40.238.939.241.4
Methotrexate, mg/week
 No use45.749.445.944.5
 ≤1047.943.547.649.4
 >10 to ≤155.15.65.24.8
 >15 to ≤201.11.41.11.2
 >200.20.20.30.1
 Not use biologic or non-biologic DMARDs13.916.714.512.7
Prednisone-equivalent steroid dose, mg/day
 No use46.757.551.239.7
 0 to ≤7.533.230.133.733.7
 >7.520.112.415.126.7
Health behaviour, %
  Prostate-specific antigen‡48.253.750.344.2
 Papanicolaou smear§12.317.213.110.4
 Mammography§43.648.347.539.1
 Qualified for Medicare for reason other than age
(eg, disability)
37.838.935.939.1
  • Note: Population shown was included for the SIE analysis. After exclusion for prevalent CHD, a subgroup of 16 796 patients was included in the MI/CHD analysis. Proportions may not sum exactly to 100% due to rounding.

  • *Measured at the time of the first MBDA test, using data from the preceding 12 months.

  • †These patients were included in infection analysis but excluded from MI and CHD analyses.

  • ‡Men only.

  • §Women only.

  • CHD, coronary heart disease; DMARD, disease-modifying antirheumatic drugs; HCQ, hydroxychloroquine; LEF, leflunomide; MBDA, multibiomarker disease activity; MI, myocardial infarction; SIE, serious infection event; SSZ, sulfasalazine.